Ovarian carcinoma subtypes are different diseases: implications for biomarker studies - Wikidata - wikimedia - TriplyDB

Ovarian carcinoma subtypes are different diseases: implications for biomarker studies

Ovarian carcinoma subtypes are different diseases: implications for biomarker studies

http://www.wikidata.org/entity/Q21563402

about

Identification of candidate biomarkers in ovarian cancer serum by depletion of highly abundant proteins and differential in-gel electrophoresis ARID1A mutations in endometriosis-associated ovarian carcinomas Epigenetic analysis leads to identification of HNF1B as a subtype-specific susceptibility gene for ovarian cancer Current Stem Cell Biomarkers and Their Functional Mechanisms in Prostate Cancer Current clinical application of serum biomarkers to detect ovarian cancer The miR-200 Family: Versatile Players in Epithelial Ovarian Cancer Emerging role of cancer stem cells in the biology and treatment of ovarian cancer: basic knowledge and therapeutic possibilities for an innovative approach The oviduct and ovarian cancer: causality, clinical implications, and "targeted prevention"An Immunohistochemical Algorithm for Ovarian Carcinoma Typing.Proteomics of ovarian cancer: functional insights and clinical applications Type-specific cell line models for type-specific ovarian cancer research Regulated proteolysis of Trop2 drives epithelial hyperplasia and stem cell self-renewal via β-catenin signaling The Potential Diagnostic Utility of TROP-2 in Thyroid Neoplasms.Single-Patient Molecular Testing with NanoString nCounter Data Using a Reference-Based Strategy for Batch Effect Correction.Molecular Subtyping of Serous Ovarian Cancer Based on Multi-omics Data.Targeted methylation of the epithelial cell adhesion molecule (EpCAM) promoter to silence its expression in ovarian cancer cells Ovarian cancer: a clinical challenge that needs some basic answers.The preclinical natural history of serous ovarian cancer: defining the target for early detection Systematic analysis of immune infiltrates in high-grade serous ovarian cancer reveals CD20, FoxP3 and TIA-1 as positive prognostic factors DNA methylation profiles of ovarian epithelial carcinoma tumors and cell lines.STAMP alters the growth of transformed and ovarian cancer cells.Hormone-receptor expression and ovarian cancer survival: an Ovarian Tumor Tissue Analysis consortium study Risk factors for epithelial ovarian cancer by histologic subtype.Use of a single-chain antibody library for ovarian cancer biomarker discovery.Molecular abnormalities in ovarian cancer subtypes other than high-grade serous carcinoma.Augmented Serum Amyloid A1/2 Mediated by TNF-induced NF-κB in Human Serous Ovarian Epithelial Tumors.Deregulation of microcephalin and ASPM expression are correlated with epithelial ovarian cancer progression.A link between mir-100 and FRAP1/mTOR in clear cell ovarian cancer FOXM1 expression is significantly associated with chemotherapy resistance and adverse prognosis in non-serous epithelial ovarian cancer patients Tumors that mimic asbestos-related mesothelioma: time to consider a genetics-based tumor registry?Expression of interleukin-1 (IL-1) ligands system in the most common endometriosis-associated ovarian cancer subtypes.Cathepsins B, L and cystatin C in cyst fluid of ovarian tumors.Clinical significance of the estrogen-modifying enzymes steroid sulfatase and estrogen sulfotransferase in epithelial ovarian cancer.Discrete mixture modeling to address genetic heterogeneity in time-to-event regression Calculator for ovarian carcinoma subtype prediction.Clinical and genetic analysis of recurrent adult-type granulosa cell tumor of the ovary: Persistent preservation of heterozygous c.402C>G FOXL2 mutation.The clinical and prognostic correlation of HRNPM and SLC1A5 in pathogenesis and prognosis in epithelial ovarian cancer.CXCL12 expression by healthy and malignant ovarian epithelial cells.Deregulation of MYCN, LIN28B and LET7 in a molecular subtype of aggressive high-grade serous ovarian cancers.Polymorphisms in stromal genes and susceptibility to serous epithelial ovarian cancer: a report from the Ovarian Cancer Association Consortium.

P2860

Q24600418-E9FB498D-688C-4A3B-BC83-FAC1A2523163 Q24610484-9A88EFE9-79BB-445E-94C9-80EB7CA8B06C Q24633316-6BDFA28A-11BB-4668-8644-7A9A04018E00 Q26742062-655419B6-96D1-442C-A453-5AA5BF0B066C Q26768709-458D269E-0083-4462-A992-2AD03DDE7838 Q26799353-CB4F816C-9F1C-4DD1-8599-530430A20802 Q26849477-C7D886B7-C2C3-46A2-9864-70B40C360E69 Q27025315-2A81ED4B-91B7-4CE0-8656-5D7F35C73368 Q27313766-ED310FD3-FC4C-44C2-A781-E6396021212F Q28082632-C67C50C6-9649-48C4-B044-F386E1DD1B65 Q28536689-78AF98F0-8C2B-4E06-8973-83E572B46A4B Q28586334-2E35AD84-C25C-4CD7-A04C-D69CC635C1D3 Q30488923-5445AAD8-CA99-4AF4-9297-990C246B922B Q31081473-18D0251D-B03D-45FE-ABDF-ABB488C6E98E Q31096420-A34EF22D-FC84-4068-A612-1782F01E4116 Q31149698-03E4E78F-EAFF-4E6C-9159-80CEACB588EC Q33405559-F2951A99-61D7-48E1-87FE-0D2DF922A724 Q33487678-64783DA2-D509-4908-9809-F4629C94A042 Q33488520-0BD25C3B-7EEF-4AE3-B41D-DD15CCA8E781 Q33533746-63F91574-82F6-4184-A0E7-FF79197BF1B2 Q33550597-0A4062ED-D1DB-4676-BE95-ABDEEFB9D294 Q33551425-DF878958-27CA-495E-8263-281ECA7C57C0 Q33552610-A33ED74B-31FC-4A0B-83E7-A085C48146BB Q33577786-B787A3D8-D33E-485E-8365-5CC6B8E92A75 Q33580777-918D4296-95E1-428E-88BE-52134066472E Q33611319-C22C1E8E-617F-40D7-8635-9B0D45C943E5 Q33617876-798AE34E-6E14-4F29-A7F9-FB3F87F03CDA Q33634277-E7E5CA48-48F9-44EF-9D7E-EC090F25788C Q33651605-2A3D2EB4-CE7B-42A6-BF9A-E581BD271A5A Q33687535-A5814306-0F2D-4A03-A122-4C4839ACE04E Q33706144-03CA3BCC-5DB7-4C28-BF6E-BCDF3C3C7A33 Q33739577-AE61A14B-690F-4FC7-B0D5-2136C20F02B0 Q33750749-F706F426-B272-4F89-9F87-A2B744015685 Q33760422-0ADBADE5-75EC-43F3-80B8-98EF3C5440F6 Q33763357-D0A3577D-2018-4EF7-9ED7-620A43343076 Q33778741-9A2620CD-5BC0-4F50-85A8-4B75BE49C16D Q33793170-134FD413-B590-48C8-A58A-BF14D3E25C17 Q33848551-C2747683-57FF-457F-8F16-6F9143C45016 Q33886925-FA683E55-3F65-4F83-9F1B-71743FA24CDC Q33921008-D2246613-CBB9-4A45-981D-9ACBE69E5AC4

P2860

Ovarian carcinoma subtypes are different diseases: implications for biomarker studies

http://www.wikidata.org/entity/Q21563402

description

2008 nî lūn-bûn

@nan

2008 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2008 թվականի դեկտեմբերին հրատարակված գիտական հոդված

@hy

2008年の論文

@ja

2008年論文

@yue

2008年論文

@zh-hant

2008年論文

@zh-hk

2008年論文

@zh-mo

2008年論文

@zh-tw

2008年论文

@wuu

name

Ovarian carcinoma subtypes are different diseases: implications for biomarker studies

@ast

Ovarian carcinoma subtypes are different diseases: implications for biomarker studies

@en

Ovarian carcinoma subtypes are different diseases: implications for biomarker studies

@en-gb

Ovarian carcinoma subtypes are different diseases: implications for biomarker studies

@nl

type

label

Ovarian carcinoma subtypes are different diseases: implications for biomarker studies

@ast

Ovarian carcinoma subtypes are different diseases: implications for biomarker studies

@en

Ovarian carcinoma subtypes are different diseases: implications for biomarker studies

@en-gb

Ovarian carcinoma subtypes are different diseases: implications for biomarker studies

@nl

altLabel

Ovarian Carcinoma Subtypes Are Different Diseases: Implications for Biomarker Studies

@en

prefLabel

Ovarian carcinoma subtypes are different diseases: implications for biomarker studies

@ast

Ovarian carcinoma subtypes are different diseases: implications for biomarker studies

@en

Ovarian carcinoma subtypes are different diseases: implications for biomarker studies

@en-gb

Ovarian carcinoma subtypes are different diseases: implications for biomarker studies

@nl

P1433

Q21563402-EBD5C637-4EBB-4676-B447-B7B7B5476F95

P1476

Q21563402-7B29D227-13F9-422A-B5F6-F0BA0C01A079

P2093

Q21563402-0722EC74-060A-4B11-9C36-BD4B189F9138

Q21563402-131AA1B3-F1E7-467C-92F2-20838244822B

Q21563402-174F280B-C6C7-44F0-BB16-CC33882703BB

Q21563402-2BC04219-E37B-4D3C-A31C-93B497FEE3C2

Q21563402-418B0C5E-C8D7-4031-8F48-8C8A1296B2ED

Q21563402-56732351-530B-4898-8FCE-665D5FF8EC03

Q21563402-56CB9630-A0A7-482C-998C-80901E67DB6C

Q21563402-6F135D60-F647-426B-808D-07205E98F707

Q21563402-6F13D149-8810-4A74-8130-13C7B06FEF35

Q21563402-AC438ADD-88CB-416A-B743-0D524219E5F4

P2860

Q21563402-106640A2-BFDD-462A-B6E7-E4291B3A8CB2

Q21563402-23082EF5-5889-4AAB-9352-87BB6E0BE46A

Q21563402-23E80FA1-C902-4353-B54E-0130C43EC7F9

Q21563402-3BC9E0E6-FBBE-4A33-9036-A5427FEACC3A

Q21563402-42CDB995-A5EE-490B-B24A-5D3688252E0B

Q21563402-43D71B01-4923-4D67-8295-F52DA9299A76

Q21563402-4C2FD448-7DF2-4A38-B665-4494D47636AE

Q21563402-551D4371-4B17-4F0B-8E6D-BEFC8FA4A428

Q21563402-5DA8824F-11A1-4210-807F-FFC39CF1E723

Q21563402-6D75510B-EEF9-409C-A364-D53B7E3AA9F2

P304

Q21563402-69378567-EFCF-48AE-8566-7AE766544090

P31

Q21563402-28E46E53-ACC9-4A4D-B178-32E0BEBB1393

P3181

Q21563402-44A61A17-97E0-4169-9615-8006DF462853

P356

Q21563402-90DF486D-7602-48C5-B68D-C98A6BB7F181

P407

Q21563402-64EB5DE3-E223-4C7B-9A0E-6B5D473D06D5

P433

Q21563402-A0679868-0FF5-4481-B18F-FF1FEEB3968E

P478

Q21563402-5E79F7D8-7B73-4B36-BC27-ABA72A6F756E

P50

Q21563402-05FEE80A-9D6F-4AA2-910A-04FDF3EF3381

P577

Q21563402-F3E31DE3-F87D-40B2-8161-F345F10D880F

P5875

Q21563402-A55652DB-9567-4738-8CC0-EF6FDB4DBD9E

P698

Q21563402-FCEEF08C-5FD9-4965-B7FA-A9BCB2873A43

P921

Q21563402-7DEE80A5-B8BA-4AB3-9318-A7C73B5475E3

P932

Q21563402-A88636EE-C61D-4C06-9B56-E292B4B5710A

P3181

P356

JOURNAL.PMED.0050232

P1433

P1476

Ovarian carcinoma subtypes are different diseases: implications for biomarker studies

@en

P2093

Ashish Rajput

http://www.w3.org/2001/XMLSchema#string

C Blake Gilks

http://www.w3.org/2001/XMLSchema#string

Chana Palmer

http://www.w3.org/2001/XMLSchema#string

David Huntsman

http://www.w3.org/2001/XMLSchema#string

Diana N Ionescu

http://www.w3.org/2001/XMLSchema#string

Dianne Miller

http://www.w3.org/2001/XMLSchema#string

Erika Mehl

http://www.w3.org/2001/XMLSchema#string

Jennifer Santos

http://www.w3.org/2001/XMLSchema#string

Kenneth Swenerton

http://www.w3.org/2001/XMLSchema#string

Leah M Prentice

http://www.w3.org/2001/XMLSchema#string

P2860

Exquisite sensitivity of TP53 mutant and basal breast cancers to a dose-dense epirubicin-cyclophosphamide regimen

A gene expression-based method to diagnose clinically distinct subgroups of diffuse large B cell lymphoma

Subclassification of ovarian surface epithelial tumors based on correlation of histologic and molecular pathologic data.

Evidence that p53-mediated cell-cycle-arrest inhibits chemotherapeutic treatment of ovarian carcinomas.

Kisspeptin and GPR54 immunoreactivity in a cohort of 518 patients defines favourable prognosis and clear cell subtype in ovarian carcinoma.

Systematic evaluation of candidate blood markers for detecting ovarian cancer.

Current understanding of the epidemiology and clinical implications of BRCA1 and BRCA2 mutations for ovarian cancer.

Ovarian tumorigenesis: a proposed model based on morphological and molecular genetic analysis.

Prognostic indices in ovarian cancer. Their significance in treatment planning.

Clear cell carcinoma of the ovary: a retrospective multicentre experience of 254 patients with complete surgical staging.

P304

e232

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

87406

http://www.w3.org/2001/XMLSchema#string

P356

10.1371/JOURNAL.PMED.0050232

http://www.w3.org/2001/XMLSchema#string

P407

P433

12

http://www.w3.org/2001/XMLSchema#string

P478

5

http://www.w3.org/2001/XMLSchema#string

P50

P577

2008-12-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

23568114

http://www.w3.org/2001/XMLSchema#string

P698

19053170

http://www.w3.org/2001/XMLSchema#string

P921

P932

2592352

http://www.w3.org/2001/XMLSchema#string